News

The Tribune16d
Low enrolment: 621 schools to be closed, merged or downgraded in Himachal
The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist ...
GEN21d
Kymera’s STAT6 Degrader for Inflammatory Disease Shows Early Success in Phase I
The trial tested the safety and efficacy of KT-621, a once-a-day drug which degrades STAT6, a signaling protein crucial in immune response. Results from the 118 healthy volunteer study showed ...
Seeking Alpha21d
Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data
Kymera Therapeutics, Inc. (NASDAQ:KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral ...
Yahoo Finance21d
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
“Our primary objective was to demonstrate that KT-621 could achieve robust STAT6 degradation in blood and skin that was well tolerated, and these results go well beyond our expectation ...
Morningstar22d
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Complete STAT6 degradation achieved in both blood and skin at all MAD doses ≥50 mg KT-621 impact on Th2 biomarkers in line or superior to dupilumab with median TARC reduction up to 37% and ...
manilatimes22d
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Complete STAT6 degradation achieved in both blood and skin at all MAD doses ≥50 mg KT-621 impact on Th2 biomarkers in line or superior to dupilumab with median TARC reduction up to 37% and median ...
Nasdaq1mon
Kymera Therapeutics Presents Promising Preclinical Data for KT-621, a First-in-Class Oral STAT6 Degrader, Demonstrating Comparable Efficacy to Dupilumab in Chronic Asthma Model
KT-621 demonstrated comparable or superior activity to dupilumab in reversing disease progression in a chronic asthma model, indicating its potential as an effective treatment option. Kymera ...
Yahoo Finance1mon
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference
“We believe KT-621 represents an enormous opportunity to expand patient access to an oral systemic advanced therapy in many common immuno-inflammatory diseases, such as asthma, that have limited ...
Morningstar1mon
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in a newly disclosed preclinical chronic asthma model reversing disease progression KT ...
Coshocton Tribune1mon
Coshocton woman flown to hospital following two-vehicle crash at Ohio 621 and U.S. 36
COSHOCTON − One woman was flown to a Columbus hospital following a two-vehicle traffic crash at approximately 12:51 p.m. May 16 at the intersection of U.S. 36 and Ohio 621 in Keene Township. Lois King ...
Sporting News1mon
Giannis Antetokounmpo may have revealed 4 teams on his trade wish list
It's not a given that Giannis Antetokounmpo is traded. But if the Milwaukee Bucks decide to move the Greek Freak, he might have a few destinations in mind. Antetokounmpo decided to hold a Q&A on X ...
Outlookindia1mon
Benfica Vs Sporting CP Live Streaming: When And Where To Watch SLB Vs SCP Primeira Liga 2024-25 Matchday 33 Fixture
Estadio da Luz is set to host the ‘Lisbon Derby’ as SL Benfica will face Sporting CP in Matchday 33 of the Portuguese Primeira Liga 2024-25 on 10 May. (More Football News) Other than being the ...